Article Details

Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma - OncLive

Retrieved on: 2024-12-10 00:08:02

Tags for this article:

Click the tags to see associated articles and topics

Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma - OncLive. View article details on hiswai:

Excerpt

The CD38-directed monoclonal antibody isatuximab (Sarclisa) combined with initial bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo